SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Novo Nordisk’s Sogroya Wins FDA Approval for Children With Turner Syndrome

The once-weekly, long-acting growth hormone is approved for appropriate children aged 2.5 and older.

NVO

Related stories